This study develops a co-modification strategy using SA2-PEG2000-CAR and SA2-PEG2000 SA2-PEG2000-CAR and SA2-PEG2000 to enhance the therapeutic potential of MSCs for IPF. The gene discussed is STAG2; the disease is idiopathic pulmonary fibrosis.